Empagliflozin in stage 4 non-diabetic kidney disease

Phase 3

Recruiting

• Conditions: Chronic kidney disease; Renal and Urogenital - Kidney disease

• Registration Number: ACTRN12622001371785
• Lead Sponsor: niversity of Otago

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-10-26
• Last Update Posted: 13 March 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

Now expanded to Individuals with non-diabetic stage 4 kidney disease with a stable eGFR between 30 and 15 ml/min/1.73m2 for the past 3 months.
No change in medications over past 3 months.
Not previously on empagliflozin.

Exclusion Criteria

.
Not able to give informed consent.

Study & Design

• Study Type: Interventional
• Study Design: Not specified